Therapeutic Asset Ratings

3,227 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
3-IODOBENZYLGUANIDINE (123I) Dementia	Mayo Clinic	P4	B (58)
3-N-BUTYLPHTHALIDE Cerebral Infarction	Qianfoshan Hospital	P4	B (58)
3-N-BUTYLPHTHALIDE Cognitive Disorder	First Affiliated Hospital of Wenzhou Medical University	P4	B (58)
Abp-688 Major Depressive Disorder	Stony Brook University	P4	B (58)
Acalabrutinib Heart Failure	AstraZeneca	P4	B (58)
Agomelatine Schizophrenia	Shanghai Mental Health Center	P4	B (58)
Allopurinol Gout	Haiphong University of Medicine and Pharmacy	P4	B (58)
Amikacin Hepatic Encephalopathy	Asian Institute of Gastroenterology, India	P4	B (58)
Amino Acids, Branched-Chain Hepatic Encephalopathy	General Hospital of Shenyang Military Region	P4	B (58)
Amitriptyline Tinnitus	Stanford University	P4	B (58)
Amlodipine Stroke Disorder	Beijing Tiantan Hospital	P4	B (58)
Antihemophilic Factor, Human Recombinant Residues 722-1672 Deleted Severe Hemophilia A	Octapharma	P4	B (58)
Apixaban Cerebral Infarction	Assistance Publique - Hôpitaux de Paris	P4	B (58)
Apixaban Hepatic Encephalopathy	Asian Institute Of Medical Sciences	P4	B (58)
Apixaban Portal Vein Thrombosis	Asian Institute Of Medical Sciences	P4	B (58)
Apsolol Tinnitus	Stanford University	P4	B (58)
Asenapine Treatment-Refractory Schizophrenia	Dr. Stavroula Rakitzi	P4	B (58)
Atogepant Tinnitus	Stanford University	P4	B (58)
Atorvastatin Dementia	Duke University	P4	B (58)
Azathioprine Hepatocellular Carcinoma	Baylor Research Institute	P4	B (58)
Biktarvy HIV Infectious Disease	East Carolina University	P4	B (58)
Binimetinib Neoplasm	Pfizer	P4	B (58)
Blood, Whole Cirrhosis Of Liver	University Hospital, Angers	P4	B (58)
Bms-986374 Relapsing-Remitting Multiple Sclerosis	Bristol-Myers Squibb	P4	B (58)
Bortezomib Peripheral Neuropathy	Tanta University	P4	B (58)

Showing 2651 to 2675 of 3,227 assets

PreviousPage 107 of 130Next